2542
K. Okuro, H. Alper / Tetrahedron Letters 53 (2012) 2540–2542
Bhargava, K. P.; Kishore, K. J. Indian Chem. Soc. 1979, 56, 219; (g) Parmar, S. S.;
Kumar, R.; Arora, R. C. J. Indian Med. Res. 1969, 57, 245; (h) Misra, V. S.; Saxena,
V. K.; Srivastava, R. Indian J. Pharm. Sci. 1983, 45, 207.
The aroylpalladium intermediate can be trapped by the internal N-
toluensulfonylamino group to complete the catalytic cycle, afford-
ing 2,3-dihydro-4(1H)-quinazolinones with the re-generation of
the Pd(0) species.
In conclusion, we have demonstrated an effective synthetic pro-
cess for the preparation of 2,3-dihydro-4(1H)-quinazolinone by
palladium catalyzed intermolecular cyclocarbonylation of 2-iodo-
anilines and N-toluenesulfonyl aldimines. Because the preparation
of 2-iodoanilines having a wide variety of functional groups has
been well established, this protocol is particularly useful for pre-
paring 2-aryl quinazolinones having functional groups on main
ring in a single step.
2. Cheng, X.; Vellalath, S.; Goddard, R.; List, B. J. Am. Chem. Soc. 2008, 130, 15786.
3. Khan, M. T. H.; Khan, R.; Wuxiuer, Y.; Arfan, M.; Ahmed, M.; Sylte, I. Bioorg. Med.
Chem. 2010, 18, 4317.
4. (a) Hour, M.-J.; Huang, L.-J.; Kuo, S.-C.; Xia, Y.; Bastow, K.; Nakanishi, Y.; Hamel,
E.; Lee, K.-H. J. Med. Chem. 2000, 43, 4479; (b) Brown, M. L. U.S. Patent
Application 2007/0134161.; (c) Kuo, S. -C.; Hour, M. -J.; Huang, L. -J.; Lee, K. -H.
U.S. Patent 6,479,499, 2002.; (d) Hamel, E.; Lin, C. M.; Plowman, J.; Wang, H.-K.;
Lee, K.-H.; Paull, K. D. Biochem. Pharm. 1996, 51, 53.
5. For example: (a) Subba Reddy, B. V.; Venkateswarlu, A.; Madan, C.; Vinu, A.
Tetrahedron Lett. 1891, 2011, 52; (b) Shaabani, A.; Maleki, A.; Mofakham, H.
Synth. Commun. 2008, 38, 3751; (c) Kassaee, M. Z.; Rostamizadeh, S.; Shadjou,
N.; Motamedi, E.; Esmaeelzadeh, M. J. Heterocycl. Chem. 2010, 47, 1421; (d)
Wang, L.-M.; Hu, L.; Shao, J.-H.; Yu, J.; Zhang, L. J. Fluorine Chem. 2008, 129,
1139.
6. Rueping, M.; Antonchick, A. P.; Sugino, E.; Grenader, K. Angew. Chem., Int. Ed.
2009, 48, 908.
Acknowledgment
7. Zheng, Z.; Alper, H. Org. Lett. 2008, 10, 829.
8. Chouhan, G.; Alper, H. Org. Lett. 2008, 10, 4987.
9. Zeng, Z.; Alper, H. Org. Lett. 2008, 10, 4903.
10. Zheng, Z.; Alper, H. Org. Lett. 2009, 11, 3278.
We are grateful to the Natural Sciences and Engineering Council
of Canada (NSERC) for support of this research.
11. Zeng, F.; Alper, H. Org. Lett. 2011, 13, 2868.
12. Zeng, F.; Alper, H. Org. Lett. 2010, 12, 5567.
References and notes
13. Zeng, F.; Alper, H. Org. Lett. 2010, 12, 3642.
14. Chouhan, G.; Alper, H. Org. Lett. 2010, 12, 192.
15. Netherton, M. R.; Fu, G. C. Org. Lett. 2001, 3, 4295.
16. Chemla, F.; Hebbe, V.; Normant, J.-F. Synthesis 2000, 16, 75.
17. Tsuji, J. Palladium Reagents and Catalysts; Wiley Sons: England, 1995.
1. (a) Parmar, S. S.; Arora, R. C. J. Med. Chem. 1967, 10, 1183; (b) Kacker, I. K.;
Zaheer, S. H. J. Indian Chem. Soc. 1951, 28, 344; (c) Shukla, J. S.; Saxena, S. J.
Indian Chem. Soc. 1979, 56, 1237; (d) Ozaki, K.; Yamada, Y.; Oine, T.; Ishizuka, T.;
Iwasawa, Y. J. Med. Chem. 1985, 28, 568; (e) Gujaral, M. L.; Saxena, P. N.; Tewari,
R. S. J. Indian Med. Res. 1955, 43, 637; (f) Gupta, R. C.; Nath, R.; Shanker, K.;